<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36798286</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>29</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2692-8205</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2023</Year><Month>Aug</Month><Day>04</Day></PubDate></JournalIssue><Title>bioRxiv : the preprint server for biology</Title><ISOAbbreviation>bioRxiv</ISOAbbreviation></Journal><ArticleTitle>Long COVID manifests with T cell dysregulation, inflammation, and an uncoordinated adaptive immune response to SARS-CoV-2.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">2023.02.09.527892</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1101/2023.02.09.527892</ELocationID><Abstract><AbstractText>Long COVID (LC), a type of post-acute sequelae of SARS-CoV-2 infection (PASC), occurs after at least 10% of SARS-CoV-2 infections, yet its etiology remains poorly understood. Here, we used multiple "omics" assays (CyTOF, RNAseq/scRNAseq, Olink) and serology to deeply characterize both global and SARS-CoV-2-specific immunity from blood of individuals with clear LC and non-LC clinical trajectories, 8 months following infection and prior to receipt of any SARS-CoV-2 vaccine. Our analysis focused on deep phenotyping of T cells, which play important roles in immunity against SARS-CoV-2 yet may also contribute to COVID-19 pathogenesis. Our findings demonstrate that individuals with LC exhibit systemic inflammation and immune dysregulation. This is evidenced by global differences in T cell subset distribution in ways that imply ongoing immune responses, as well as by sex-specific perturbations in cytolytic subsets. Individuals with LC harbored increased frequencies of CD4+ T cells poised to migrate to inflamed tissues, and exhausted SARS-CoV-2-specific CD8+ T cells. They also harbored significantly higher levels of SARS-CoV-2 antibodies, and in contrast to non-LC individuals, exhibited a mis-coordination between their SARS-CoV-2-specific T and B cell responses. RNAseq/scRNAseq and Olink analyses similarly revealed immune dysregulatory mechanisms, along with non-immune associated perturbations, in individuals with LC. Collectively, our data suggest that proper crosstalk between the humoral and cellular arms of adaptive immunity has broken down in LC, and that this, perhaps in the context of persistent virus, leads to the immune dysregulation, inflammation, and clinical symptoms associated with this debilitating condition.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yin</LastName><ForeName>Kailin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Gladstone Institutes, University of California, San Francisco, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Urology, University of California, San Francisco, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peluso</LastName><ForeName>Michael J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luo</LastName><ForeName>Xiaoyu</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Gladstone Institutes, University of California, San Francisco, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Urology, University of California, San Francisco, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thomas</LastName><ForeName>Reuben</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Gladstone Institutes, University of California, San Francisco, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shin</LastName><ForeName>Min-Gyoung</ForeName><Initials>MG</Initials><AffiliationInfo><Affiliation>Gladstone Institutes, University of California, San Francisco, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Neidleman</LastName><ForeName>Jason</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Gladstone Institutes, University of California, San Francisco, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Urology, University of California, San Francisco, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andrew</LastName><ForeName>Alicer</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Gladstone Institutes, University of California, San Francisco, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Urology, University of California, San Francisco, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Young</LastName><ForeName>Kyrlia</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Gladstone Institutes, University of California, San Francisco, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Urology, University of California, San Francisco, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Tongcui</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Gladstone Institutes, University of California, San Francisco, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Urology, University of California, San Francisco, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hoh</LastName><ForeName>Rebecca</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Anglin</LastName><ForeName>Khamal</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Beatrice</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Argueta</LastName><ForeName>Urania</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lopez</LastName><ForeName>Monica</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Valdivieso</LastName><ForeName>Daisy</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Asare</LastName><ForeName>Kofi</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deveau</LastName><ForeName>Tyler-Marie</ForeName><Initials>TM</Initials><AffiliationInfo><Affiliation>Division of Experimental Medicine, University of California, San Francisco, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Munter</LastName><ForeName>Sadie E</ForeName><Initials>SE</Initials><AffiliationInfo><Affiliation>Division of Experimental Medicine, University of California, San Francisco, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ibrahim</LastName><ForeName>Rania</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>St&#xe4;ndker</LastName><ForeName>Ludger</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Core Facility Functional Peptidomics, Ulm University Medical Center, Meyerhofstrasse 1, Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Scott</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, University of California, San Francisco, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goldberg</LastName><ForeName>Sarah A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, University of California, San Francisco, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Sulggi A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Zuckerberg San Francisco General Hospital and the University of California, San Francisco, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lynch</LastName><ForeName>Kara L</ForeName><Initials>KL</Initials><AffiliationInfo><Affiliation>Division of Laboratory Medicine, University of California, San Francisco, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kelly</LastName><ForeName>J Daniel</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, University of California, San Francisco, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martin</LastName><ForeName>Jeffrey N</ForeName><Initials>JN</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, University of California, San Francisco, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>M&#xfc;nch</LastName><ForeName>Jan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Core Facility Functional Peptidomics, Ulm University Medical Center, Meyerhofstrasse 1, Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deeks</LastName><ForeName>Steven G</ForeName><Initials>SG</Initials><AffiliationInfo><Affiliation>Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Henrich</LastName><ForeName>Timothy J</ForeName><Initials>TJ</Initials><AffiliationInfo><Affiliation>Division of Experimental Medicine, University of California, San Francisco, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roan</LastName><ForeName>Nadia R</ForeName><Initials>NR</Initials><AffiliationInfo><Affiliation>Gladstone Institutes, University of California, San Francisco, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Urology, University of California, San Francisco, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AI158013</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 DK063720</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 AI157875</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>S10 RR028962</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>S10 OD018040</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AI141003</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>L30 AI147159</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>L30 AI126521</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 AI146268</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D000076942">Preprint</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>08</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>bioRxiv</MedlineTA><NlmUniqueID>101680187</NlmUniqueID><ISSNLinking>2692-8205</ISSNLinking></MedlineJournalInfo><CommentsCorrectionsList><CommentsCorrections RefType="UpdateIn"><RefSource>Nat Immunol. 2024 Feb;25(2):218-225. doi: 10.1038/s41590-023-01724-6</RefSource><PMID Version="1">38212464</PMID></CommentsCorrections></CommentsCorrectionsList><CoiStatement>CONFLICTS OF INTERESTS MJP reports consulting fees from Gilead Sciences and AstraZeneca, outside the submitted work. SGD reports grants and/or personal fees from Gilead Sciences, Merck &amp; Co., Viiv, AbbVie, Eli Lilly, ByroLogyx, and Enochian Biosciences, outside the submitted work. TJH receives grant support from Merck and consults for Roche. All other authors report no potential conflicts.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>2</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>2</Month><Day>18</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>2</Month><Day>17</Day><Hour>2</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>8</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36798286</ArticleId><ArticleId IdType="pmc">PMC9934605</ArticleId><ArticleId IdType="doi">10.1101/2023.02.09.527892</ArticleId><ArticleId IdType="pii">2023.02.09.527892</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Nalbandian A. et al. Post-acute COVID-19 syndrome. Nat. Med. (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso M.J. &amp; Deeks S.G. Early clues regarding the pathogenesis of long-COVID. Trends Immunol. 43, 268&#x2013;270 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8901423</ArticleId><ArticleId IdType="pubmed">35272932</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis H.E., McCorkell L., Vogel J.M. &amp; Topol E.J. Long COVID: major findings, mechanisms and recommendations. Nature Reviews Microbiology, 1&#x2013;14 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9839201</ArticleId><ArticleId IdType="pubmed">36639608</ArticleId></ArticleIdList></Reference><Reference><Citation>Azzolini E. et al. Association Between BNT162b2 Vaccination and Long COVID After Infections Not Requiring Hospitalization in Health Care Workers. JAMA (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9250078</ArticleId><ArticleId IdType="pubmed">35796131</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayoubkhani D. et al. Trajectory of long covid symptoms after covid-19 vaccination: community based cohort study. BMJ 377, e069676 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9115603</ArticleId><ArticleId IdType="pubmed">35584816</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Aly Z., Bowe B. &amp; Xie Y. Long COVID after breakthrough SARS-CoV-2 infection. Nat. Med., 1&#x2013;7 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9307472</ArticleId><ArticleId IdType="pubmed">35614233</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y., Choi T. &amp; Al-Aly Z. Nirmatrelvir and the Risk of Post-Acute Sequelae of COVID-19.</Citation></Reference><Reference><Citation>Wynberg E. et al. The effect of SARS-CoV-2 vaccination on post-acute sequelae of COVID-19 (PASC): A prospective cohort study. Vaccine 40, 4424&#x2013;4431 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9170535</ArticleId><ArticleId IdType="pubmed">35725782</ArticleId></ArticleIdList></Reference><Reference><Citation>Ambrosino P. et al. Clinical assessment of endothelial function in convalescent COVID-19 patients: a meta-analysis with meta-regressions. Ann. Med. 54, 3234&#x2013;3249 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9673781</ArticleId><ArticleId IdType="pubmed">36382632</ArticleId></ArticleIdList></Reference><Reference><Citation>Pretorius E. et al. Prevalence of symptoms, comorbidities, fibrin amyloid microclots and platelet pathology in individuals with Long COVID/Post-Acute Sequelae of COVID-19 (PASC). Cardiovasc. Diabetol. 21, 148 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9356426</ArticleId><ArticleId IdType="pubmed">35933347</ArticleId></ArticleIdList></Reference><Reference><Citation>See&#xdf;le J. et al. Persistent symptoms in adult patients one year after COVID-19: a prospective cohort study. Clin. Infect. Dis. (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8394862</ArticleId><ArticleId IdType="pubmed">34223884</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y. et al. Multiple Early Factors Anticipate Post-Acute COVID-19 Sequelae. Cell 0 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8786632</ArticleId><ArticleId IdType="pubmed">35216672</ArticleId></ArticleIdList></Reference><Reference><Citation>Son K. et al. Circulating anti-nuclear autoantibodies in COVID-19 survivors predict long-COVID symptoms. Eur. Respir. J. (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9515477</ArticleId><ArticleId IdType="pubmed">36137590</ArticleId></ArticleIdList></Reference><Reference><Citation>Gold J.E., Okyay R.A., Licht W.E. &amp; Hurley D.J. Investigation of long COVID prevalence and its relationship to Epstein-Barr virus reactivation. Pathogens 10, 763 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8233978</ArticleId><ArticleId IdType="pubmed">34204243</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso M.J. et al. Impact of pre-existing chronic viral infection and reactivation on the development of long COVID. The Journal of Clinical Investigation (2022).</Citation></Reference><Reference><Citation>Stein S.R. et al. SARS-CoV-2 infection and persistence in the human body and brain at autopsy. Nature, 1&#x2013;6 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9749650</ArticleId><ArticleId IdType="pubmed">36517603</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso M.J. et al. SARS-CoV-2 and Mitochondrial Proteins in Neural-Derived Exosomes of COVID-19. Ann. Neurol. (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9082480</ArticleId><ArticleId IdType="pubmed">35285072</ArticleId></ArticleIdList></Reference><Reference><Citation>Swank Z. et al. Persistent circulating SARS-CoV-2 spike is associated with post-acute COVID-19 sequelae. Clin. Infect. Dis. (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10169416</ArticleId><ArticleId IdType="pubmed">36052466</ArticleId></ArticleIdList></Reference><Reference><Citation>Natarajan A. et al. Gastrointestinal symptoms and fecal shedding of SARS-CoV-2 RNA suggest prolonged gastrointestinal infection. Med (N Y) (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9005383</ArticleId><ArticleId IdType="pubmed">35434682</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein J. et al. Distinguishing features of Long COVID identified through immune profiling. medRxiv (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10620090</ArticleId><ArticleId IdType="pubmed">37748514</ArticleId></ArticleIdList></Reference><Reference><Citation>Phetsouphanh C. et al. Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection. Nat. Immunol., 1&#x2013;7 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35027728</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso M.J. et al. Markers of Immune Activation and Inflammation in Individuals With Postacute Sequelae of Severe Acute Respiratory Syndrome Coronavirus 2 Infection. J. Infect. Dis. (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8643408</ArticleId><ArticleId IdType="pubmed">34677601</ArticleId></ArticleIdList></Reference><Reference><Citation>Giron L.B. et al. Markers of fungal translocation are elevated during post-acute sequelae of SARS-CoV-2 and induce NF-&#x3ba;B signaling. JCI Insight 7 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9462470</ArticleId><ArticleId IdType="pubmed">35727635</ArticleId></ArticleIdList></Reference><Reference><Citation>Vijayakumar B. et al. Immuno-proteomic profiling reveals aberrant immune cell regulation in the airways of individuals with ongoing post-COVD-19 respiratory disease. Immunity 0 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8789571</ArticleId><ArticleId IdType="pubmed">35151371</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulthei&#xdf; C. et al. The IL-1&#x3b2;, IL-6, and TNF cytokine triad is associated with post-acute sequelae of COVID-19. Cell Rep Med 3, 100663 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9214726</ArticleId><ArticleId IdType="pubmed">35732153</ArticleId></ArticleIdList></Reference><Reference><Citation>Littlefield K.M. et al. SARS-CoV-2-specific T cells associate with inflammation and reduced lung function in pulmonary post-acute sequalae of SARS-CoV-2. PLoS Pathog 18, e1010359 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9176759</ArticleId><ArticleId IdType="pubmed">35617421</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso M.J., Thomas I.J., Munter S.E., Deeks S.G. &amp; Henrich T.J. Lack of Antinuclear Antibodies in Convalescent Coronavirus Disease 2019 Patients With Persistent Symptoms. Clinical Infectious Diseases 74, 2083&#x2013;2084 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9187313</ArticleId><ArticleId IdType="pubmed">34617982</ArticleId></ArticleIdList></Reference><Reference><Citation>Bodansky A. et al. Autoantigen profiling reveals a shared post-COVID signature in fully recovered and long COVID patients. JCI Insight 8 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10393220</ArticleId><ArticleId IdType="pubmed">37288661</ArticleId></ArticleIdList></Reference><Reference><Citation>Muri J. et al. Autoantibodies against chemokines post-SARS-CoV-2 infection correlate with disease course. Nature immunology, 1&#x2013;8 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10063443</ArticleId><ArticleId IdType="pubmed">36879067</ArticleId></ArticleIdList></Reference><Reference><Citation>Files J.K. et al. Duration of post-COVID-19 symptoms is associated with sustained SARSCoV-2-specific immune responses. JCI Insight 6 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8410022</ArticleId><ArticleId IdType="pubmed">34143754</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso M.J. et al. Long-term SARS-CoV-2-specific immune and inflammatory responses in individuals recovering from COVID-19 with and without post-acute symptoms. Cell Rep 36, 109518 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8342976</ArticleId><ArticleId IdType="pubmed">34358460</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma T. et al. Protracted yet Coordinated Differentiation of Long-Lived SARS-CoV-2-Specific CD8(+) T Cells during Convalescence. J Immunol 207, 1344&#x2013;1356 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8763019</ArticleId><ArticleId IdType="pubmed">34389625</ArticleId></ArticleIdList></Reference><Reference><Citation>Neidleman J. et al. SARS-CoV-2-Specific T Cells Exhibit Phenotypic Features of Helper Function, Lack of Terminal Differentiation, and High Proliferation Potential. Cell Rep Med 1, 100081 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7437502</ArticleId><ArticleId IdType="pubmed">32839763</ArticleId></ArticleIdList></Reference><Reference><Citation>Neidleman J. et al. Distinctive features of SARS-CoV-2-specific T cells predict recovery from severe COVID-19. Cell Rep 36, 109414 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8238659</ArticleId><ArticleId IdType="pubmed">34260965</ArticleId></ArticleIdList></Reference><Reference><Citation>Neidleman J. et al. mRNA vaccine-induced T cells respond identically to SARS-CoV-2 variants of concern but differ in longevity and homing properties depending on prior infection status. Elife 10 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8545397</ArticleId><ArticleId IdType="pubmed">34636722</ArticleId></ArticleIdList></Reference><Reference><Citation>Suryawanshi R.K. et al. Limited cross-variant immunity from SARS-CoV-2 Omicron without vaccination. Nature 607, 351&#x2013;355 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9279157</ArticleId><ArticleId IdType="pubmed">35584773</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso M.J. et al. Persistence, Magnitude, and Patterns of Postacute Symptoms and Quality of Life Following Onset of SARS-CoV-2 Infection: Cohort Description and Approaches for Measurement. Open Forum Infect Dis 9, ofab640 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8755302</ArticleId><ArticleId IdType="pubmed">35106317</ArticleId></ArticleIdList></Reference><Reference><Citation>Rydyznski Moderbacher C. et al. Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity. Cell 183, 996&#x2013;1012 e1019 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7494270</ArticleId><ArticleId IdType="pubmed">33010815</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersson K.M. et al. Survivin co-ordinates formation of follicular T-cells acting in synergy with Bcl-6. Oncotarget 6, 20043 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4652986</ArticleId><ArticleId IdType="pubmed">26343374</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson R.C. et al. Molecular states during acute COVID-19 reveal distinct etiologies of long-term sequelae. Nature Medicine, 1&#x2013;11 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9873574</ArticleId><ArticleId IdType="pubmed">36482101</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso M.J. et al. Effect of oral nirmatrelvir on long COVID Symptoms: 4 cases and rationale for systematic studies. Pathogens and Immunity 7, 95 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9254867</ArticleId><ArticleId IdType="pubmed">35800257</ArticleId></ArticleIdList></Reference><Reference><Citation>Geng L.N., Bonilla H.F., Shafer R.W., Miglis M.G. &amp; Yang P.C. Case report of breakthrough long COVID and the use of nirmatrelvir-ritonavir. (2022).</Citation></Reference><Reference><Citation>Visvabharathy L., Orban Z.S. &amp; Koralnik I.J. Treatment of Long COVID with nirmatrelvir/ritonavir and tocilizumab in a patient with rheumatoid arthritis and SARSCoV-2 antigen persistence: a case report. (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9537824</ArticleId><ArticleId IdType="pubmed">36213654</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi T. et al. Sex differences in immune responses that underlie COVID-19 disease outcomes. Nature 588, 315&#x2013;320 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7725931</ArticleId><ArticleId IdType="pubmed">32846427</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudre C.H. et al. Attributes and predictors of long COVID. Nature medicine 27, 626&#x2013;631 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7611399</ArticleId><ArticleId IdType="pubmed">33692530</ArticleId></ArticleIdList></Reference><Reference><Citation>Sparks R. et al. Influenza vaccination reveals sex dimorphic imprints of prior mild COVID-19. Nature, 1&#x2013;3 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10481789</ArticleId><ArticleId IdType="pubmed">36599369</ArticleId></ArticleIdList></Reference><Reference><Citation>Eddins D.J. et al. Transcriptional reprogramming of infiltrating neutrophils drives lung disease in severe COVID-19 despite low viral load. Blood Advances (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9906672</ArticleId><ArticleId IdType="pubmed">36399523</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma T. et al. Post-acute immunological and behavioral sequelae in mice after Omicron infection. bioRxiv, 2023.2006. 2005.543758 (2023).</Citation></Reference><Reference><Citation>Siewe B., Nipper A.J., Sohn H., Stapleton J.T. &amp; Landay A. FcRL4 expression identifies a pro-inflammatory B cell subset in viremic HIV-infected subjects. Frontiers in immunology 8, 1339 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5655023</ArticleId><ArticleId IdType="pubmed">29104574</ArticleId></ArticleIdList></Reference><Reference><Citation>Durstenfeld M.S. et al. Role of antibodies, inflammatory markers, and echocardiographic findings in post-acute cardiopulmonary symptoms after SARS-CoV-2 infection. MedRxiv (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9220849</ArticleId><ArticleId IdType="pubmed">35389890</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso M.J. et al. Plasma markers of neurologic injury and inflammation in people with self-reported neurologic postacute sequelae of SARS-CoV-2 infection. Neurology-Neuroimmunology Neuroinflammation 9 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9210548</ArticleId><ArticleId IdType="pubmed">35701186</ArticleId></ArticleIdList></Reference><Reference><Citation>Krishna B.A. et al. Evidence of previous SARS-CoV-2 infection in seronegative patients with long COVID. EBioMedicine 81, 104129 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9235296</ArticleId><ArticleId IdType="pubmed">35772216</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel H. et al. Proteomic blood profiling in mild, severe and critical COVID-19 patients. Scientific reports 11, 1&#x2013;12 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7973581</ArticleId><ArticleId IdType="pubmed">33737684</ArticleId></ArticleIdList></Reference><Reference><Citation>Bozorgmehr N. et al. Galectin-9, a player in cytokine release syndrome and a surrogate diagnostic biomarker in SARS-CoV-2 infection. MBio 12, e00384&#x2013;00321 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8262904</ArticleId><ArticleId IdType="pubmed">33947753</ArticleId></ArticleIdList></Reference><Reference><Citation>Du L. et al. Human Galectin-9 Potently Enhances SARS-CoV-2 Replication and Inflammation in Airway Epithelial Cells (preprint). (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10668544</ArticleId><ArticleId IdType="pubmed">37127426</ArticleId></ArticleIdList></Reference><Reference><Citation>Gardinassi L.G., Souza C.O., Sales-Campos H. &amp; Fonseca S.G. Immune and metabolic signatures of COVID-19 revealed by transcriptomics data reuse. Frontiers in immunology 11, 1636 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7332781</ArticleId><ArticleId IdType="pubmed">32670298</ArticleId></ArticleIdList></Reference><Reference><Citation>Su W.-L. et al. Desaturation and heme elevation during COVID-19 infection: A potential prognostic factor of heme oxygenase-1. Journal of Microbiology, Immunology and Infection 54, 113&#x2013;116 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7566820</ArticleId><ArticleId IdType="pubmed">33176981</ArticleId></ArticleIdList></Reference><Reference><Citation>Hopp M.T., Rathod D.C. &amp; Imhof D. Host and viral proteins involved in SARS-CoV-2 infection differentially bind heme. Protein Science 31, e4451 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9538320</ArticleId><ArticleId IdType="pubmed">36161737</ArticleId></ArticleIdList></Reference><Reference><Citation>Kronstein-Wiedemann R. et al. SARS-CoV-2 Infects red blood cell progenitors and dysregulates hemoglobin and iron metabolism. Stem Cell Reviews and Reports, 1&#x2013;13 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8856880</ArticleId><ArticleId IdType="pubmed">35181867</ArticleId></ArticleIdList></Reference><Reference><Citation>Lechuga G.C. et al. SARS-CoV-2 proteins bind to hemoglobin and its metabolites. International Journal of Molecular Sciences 22, 9035 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8396565</ArticleId><ArticleId IdType="pubmed">34445741</ArticleId></ArticleIdList></Reference><Reference><Citation>Grobbelaar L.M. et al. Relative hypercoagulopathy of the SARS-CoV-2 beta and delta variants when compared to the less severe omicron variants is related to TEG parameters, the extent of fibrin amyloid microclots, and the severity of clinical illness. Seminars in thrombosis and hemostasis; 2022: Thieme Medical Publishers, Inc.; 2022.</Citation><ArticleIdList><ArticleId IdType="pubmed">36174604</ArticleId></ArticleIdList></Reference><Reference><Citation>Kruger A. et al. Proteomics of fibrin amyloid microclots in long COVID/post-acute sequelae of COVID-19 (PASC) shows many entrapped pro-inflammatory molecules that may also contribute to a failed fibrinolytic system. Cardiovascular Diabetology 21, 1&#x2013;23 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9491257</ArticleId><ArticleId IdType="pubmed">36131342</ArticleId></ArticleIdList></Reference><Reference><Citation>Kell D.B., Laubscher G.J. &amp; Pretorius E. A central role for amyloid fibrin microclots in long COVID/PASC: origins and therapeutic implications. Biochemical Journal 479, 537&#x2013;559 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8883497</ArticleId><ArticleId IdType="pubmed">35195253</ArticleId></ArticleIdList></Reference><Reference><Citation>George A.F. et al. Deep Phenotypic Analysis of Blood and Lymphoid T and NK Cells From HIV+ Controllers and ART-Suppressed Individuals. Front Immunol 13, 803417 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8829545</ArticleId><ArticleId IdType="pubmed">35154118</ArticleId></ArticleIdList></Reference><Reference><Citation>Neidleman J. et al. Phenotypic analysis of the unstimulated in vivo HIV CD4 T cell reservoir. Elife 9, e60933 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7524554</ArticleId><ArticleId IdType="pubmed">32990219</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsampasian V. et al. Risk Factors Associated With Post-COVID-19 Condition: A Systematic Review and Meta-analysis. JAMA Intern Med (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10037203</ArticleId><ArticleId IdType="pubmed">36951832</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferretti A.P. et al. Unbiased Screens Show CD8(+) T Cells of COVID-19 Patients Recognize Shared Epitopes in SARS-CoV-2 that Largely Reside outside the Spike Protein. Immunity 53, 1095&#x2013;1107 e1093 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7574860</ArticleId><ArticleId IdType="pubmed">33128877</ArticleId></ArticleIdList></Reference><Reference><Citation>Costantini A. et al. Effects of cryopreservation on lymphocyte immunophenotype and function. Journal of immunological methods 278, 145&#x2013;155 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12957403</ArticleId></ArticleIdList></Reference><Reference><Citation>Cavrois M. et al. Mass cytometric analysis of HIV entry, replication, and remodeling in tissue CD4+ T cells. Cell reports 20, 984&#x2013;998 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5560086</ArticleId><ArticleId IdType="pubmed">28746881</ArticleId></ArticleIdList></Reference><Reference><Citation>Steiner S. et al. SARS-CoV-2 T Cell Response in Severe and Fatal COVID-19 in Primary Antibody Deficiency Patients Without Specific Humoral Immunity. Front Immunol 13, 840126 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8960624</ArticleId><ArticleId IdType="pubmed">35359967</ArticleId></ArticleIdList></Reference><Reference><Citation>Roederer M., Nozzi J.L. &amp; Nason M.C. SPICE: exploration and analysis of post-cytometric complex multivariate datasets. Cytometry A 79, 167&#x2013;174 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3072288</ArticleId><ArticleId IdType="pubmed">21265010</ArticleId></ArticleIdList></Reference><Reference><Citation>Hao Y. et al. Integrated analysis of multimodal single-cell data. Cell 184, 3573&#x2013;3587 e3529 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8238499</ArticleId><ArticleId IdType="pubmed">34062119</ArticleId></ArticleIdList></Reference><Reference><Citation>Korsunsky I. et al. Fast, sensitive and accurate integration of single-cell data with Harmony. Nat Methods 16, 1289&#x2013;1296 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6884693</ArticleId><ArticleId IdType="pubmed">31740819</ArticleId></ArticleIdList></Reference><Reference><Citation>Breiman L. Random forests. Machine learning 45, 5&#x2013;32 (2001).</Citation></Reference><Reference><Citation>Bates D., M&#xe4;chler M., Bolker B. &amp; Walker S. Fitting linear mixed-effects models using lme4. arXiv preprint arXiv:1406.5823 (2014).</Citation></Reference><Reference><Citation>Lenth R., Singmann H., Love J., Buerkner P. &amp; Herve M. Emmeans: Estimated marginal means, aka least-squares means. R package version 1, 3 (2018).</Citation></Reference><Reference><Citation>Dobin A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15&#x2013;21 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3530905</ArticleId><ArticleId IdType="pubmed">23104886</ArticleId></ArticleIdList></Reference><Reference><Citation>Love M.I., Huber W. &amp; Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome biology 15, 1&#x2013;21 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4302049</ArticleId><ArticleId IdType="pubmed">25516281</ArticleId></ArticleIdList></Reference><Reference><Citation>Vvan der Laan M. &amp; Pollard K. Hybrid clustering of gene expression data with visualization and the bootstrap. Journal of Statistical Planning and Inference 117, 275&#x2013;303 (2003).</Citation></Reference><Reference><Citation>Zheng G.X. et al. Massively parallel digital transcriptional profiling of single cells. Nature communications 8, 14049 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5241818</ArticleId><ArticleId IdType="pubmed">28091601</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahlmann-Eltze C. &amp; Huber W. glmGamPoi: fitting Gamma-Poisson generalized linear models on single cell count data. Bioinformatics 36, 5701&#x2013;5702 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8023675</ArticleId><ArticleId IdType="pubmed">33295604</ArticleId></ArticleIdList></Reference><Reference><Citation>Blondel V.D., Guillaume J.-L., Lambiotte R. &amp; Lefebvre E. Fast unfolding of communities in large networks. Journal of statistical mechanics: theory and experiment 2008, P10008 (2008).</Citation></Reference><Reference><Citation>McGinnis C.S. et al. No detectable alloreactive transcriptional responses under standard sample preparation conditions during donor-multiplexed single-cell RNA sequencing of peripheral blood mononuclear cells. BMC biology 19, 1&#x2013;11 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7816397</ArticleId><ArticleId IdType="pubmed">33472616</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu C. et al. Comprehensive multi-omics single-cell data integration reveals greater heterogeneity in the human immune system. Iscience 25, 105123 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9523353</ArticleId><ArticleId IdType="pubmed">36185375</ArticleId></ArticleIdList></Reference><Reference><Citation>Ianevski A., Giri A.K. &amp; Aittokallio T. Fully-automated and ultra-fast cell-type identification using specific marker combinations from single-cell transcriptomic data. Nature communications 13, 1246 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8913782</ArticleId><ArticleId IdType="pubmed">35273156</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson M.D., McCarthy D.J. &amp; Smyth G.K. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. bioinformatics 26, 139&#x2013;140 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2796818</ArticleId><ArticleId IdType="pubmed">19910308</ArticleId></ArticleIdList></Reference><Reference><Citation>Holm S. A simple sequentially rejective multiple test procedure. Scandinavian journal of statistics, 65&#x2013;70 (1979).</Citation></Reference><Reference><Citation>Benjamini Y. &amp; Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. Journal of the Royal statistical society: series B (Methodological) 57, 289&#x2013;300 (1995).</Citation></Reference><Reference><Citation>Crowell H, Germain P, Soneson C, Sonrel A &amp; R. muscat M: Multi-sample multi-group scRNA-seq data analysis tools. 10.18129/B9.bioc.muscat, R package version 1.14.10 (2023).</Citation><ArticleIdList><ArticleId IdType="doi">10.18129/B9.bioc.muscat</ArticleId></ArticleIdList></Reference><Reference><Citation>Assarsson E. et al. Homogenous 96-plex PEA immunoassay exhibiting high sensitivity, specificity, and excellent scalability. PloS one 9, e95192 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3995906</ArticleId><ArticleId IdType="pubmed">24755770</ArticleId></ArticleIdList></Reference><Reference><Citation>B&#xe4;ckryd E., Tanum L., Lind A.-L., Larsson A. &amp; Gordh T. Evidence of both systemic inflammation and neuroinflammation in fibromyalgia patients, as assessed by a multiplex protein panel applied to the cerebrospinal fluid and to plasma. Journal of pain research 10, 515 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5344444</ArticleId><ArticleId IdType="pubmed">28424559</ArticleId></ArticleIdList></Reference><Reference><Citation>Bj&#xf6;rkesten J. et al. Stability of proteins in dried blood spot biobanks. Molecular &amp; Cellular Proteomics 16, 1286&#x2013;1296 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5500761</ArticleId><ArticleId IdType="pubmed">28501802</ArticleId></ArticleIdList></Reference><Reference><Citation>Wigren M. et al. Decreased levels of stem cell factor in subjects with incident coronary events. Journal of internal medicine 279, 180&#x2013;191 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26467529</ArticleId></ArticleIdList></Reference><Reference><Citation>Loskog A. et al. Immunostimulatory AdCD40L gene therapy combined with low-dose cyclophosphamide in metastatic melanoma patients. British journal of cancer 114, 872&#x2013;880 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4984796</ArticleId><ArticleId IdType="pubmed">27031851</ArticleId></ArticleIdList></Reference><Reference><Citation>Kolde R. &amp; Kolde M.R. Package &#x2018;pheatmap&#x2019;. R package 1 (2018).</Citation></Reference><Reference><Citation>Doncheva N.T., Morris J.H., Gorodkin J. &amp; Jensen L.J. Cytoscape StringApp: network analysis and visualization of proteomics data. Journal of proteome research 18, 623&#x2013;632 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6800166</ArticleId><ArticleId IdType="pubmed">30450911</ArticleId></ArticleIdList></Reference><Reference><Citation>Shannon P. et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome research 13, 2498&#x2013;2504 (2003).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC403769</ArticleId><ArticleId IdType="pubmed">14597658</ArticleId></ArticleIdList></Reference><Reference><Citation>Organization, W.H.
A clinical case definition of post COVID-19 condition by a Delphi consensus, 6 October 2021. WHO/2019-nCoV/Post_COVID-19_condition/Clinical_case_definition/2021.1 (2021).</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>